EUVIMEDEUVIMED entdecken
Vergleichsstudie

A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia

Rongqi Li, Chenxiang Wang, Zhongjiang Ye, Yizhang Chen, Jingyao Xu, Chuang Chen, Jianhui Yang, Jing Fu, Tao Zhou, Ziye Zhou, Xiuhua Zhang

Expert Review of Pharmacoeconomics & Outcomes Research · 2024

DOI: 10.1080/14737167.2023.2288683 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Rongqi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Piperidines, Adenine, Cost-Benefit Analysis, Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Research Support Project for Pharmacoeconomics and Health Technology Evaluation of Zhejiang Provincial Pharmaceutical Association, Medical Health Science and Technology Project of Zhejiang Provincial Health Commission, A Project Supported by Scientific Research Fund of Zhejiang Provincial Education Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This article examined the cost-effectiveness of zanubrutinib and ibrutinib for managing relapsed and refractory chronic lymphocytic leukemia from the viewpoint of payers in China and the US. METHODS: Markov models were employed to conduct comparisons. Baseline characteristics and clinical data were extracted from the ALPINE study. The cost-effectiveness outcome indicators encompassed cost, quality-adjusted life years, and the incremental cost-effectiveness ratio. RESULTS: The Markov model analysis revealed that the zanubrutinib group incurred an incremental cost per patient of $-24,586.53 compared to the ibrutinib group. The zanubrutinib group exhibited an incremental utility per capita of 0.28 quality-adjusted life years, resulting in an incremental cost-effectiveness ratio of $-88,068.16 per quality-adjusted life year, which is lower than the payment threshold in China. The willingness-to-pay value in China for 2022 was three times the country's gross domestic product per capita. In the US, patients in the zanubrutinib group experienced per capita incremental costs of $-79,421.56, per capita incremental utility of 0.28 quality-adjusted life years, and an incremental cost-effectiveness ratio of $-284,485.45 per quality-adjusted life year. CONCLUSION: For Chinese payers, zanubrutinib exhibited superior cost-effectiveness compared to ibrutinib. Zanubrutinib proved to be a more affordable option for US payers when considering the payment threshold.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesAdenineCost-Benefit AnalysisLeukemia, Lymphocytic, Chronic, B-CellMarkov ChainsPyrimidinesQuality-Adjusted Life YearsPyrazolesHumansChinaUnited StatesAntineoplastic AgentsRecurrenceMiddle AgedMaleFemaleAgedCost-Effectiveness Analysis

Stichwörter der Autor:innen

Ibrutinibcost-effectivenesspharmacoeconomic evaluationrelapsed refractory chronic lymphocytic leukemiazanubrutinib

Substanzen

ibrutinibPiperidinesAdeninePyrimidinesPyrazoleszanubrutinibAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Pharmacy, Zhejiang University of Traditional Chinese Medicine Affiliated Wenzhou Hospital, Wenzhou, Zhejiang, China.
  • Clinical Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Förderung

  • Research Support Project for Pharmacoeconomics and Health Technology Evaluation of Zhejiang Provincial Pharmaceutical Association
  • Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
  • A Project Supported by Scientific Research Fund of Zhejiang Provincial Education Department

Zitieren

APA

Li, R., Wang, C., Ye, Z., Chen, Y., Xu, J., Chen, C., Yang, J., Fu, J., Zhou, T., Zhou, Z., & Zhang, X. (2024). A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2023.2288683

Vancouver

Li R, Wang C, Ye Z, Chen Y, Xu J, Chen C, et al. A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2023.2288683

BibTeX
@article{Li2024,
  author = {Li, Rongqi and Wang, Chenxiang and Ye, Zhongjiang and Chen, Yizhang and Xu, Jingyao and Chen, Chuang and Yang, Jianhui and Fu, Jing and Zhou, Tao and Zhou, Ziye and Zhang, Xiuhua},
  title = {A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2024},
  doi = {10.1080/14737167.2023.2288683}
}
Kostenlos starten →